Hydroxyurea in sickle cell disease-A study of clinico-pharmacological efficacy in the Indian haplotype

Blood Cells, Molecules, and Diseases

Volumn 42, Issue 1, 2009, Pages 25-31

  Italia, Khushnooma ^a   Jain, Dipty ^c   Gattani, Sushma ^c   Jijina, Farah ^b   Nadkarni, Anita ^a   Sawant, Pratibha ^a   Nair, Sona ^a   Mohanty, Dipika ^a   Ghosh, Kanjaksha ^a   Colah, Roshan ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^b KEM HOSPITAL   (India)

^c GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

thalassemia; s haplotype; HbF; Hydroxyurea; Sickle cell anemia

Indexed keywords

CYTODROX; HEMOGLOBIN F; HYDROXYUREA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALPHA THALASSEMIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DELETION; HAPLOTYPE; HEMATOLOGICAL PARAMETERS; HUMAN; INDIAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-GLOBINS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; ETHNIC GROUPS; FEMALE; FETAL HEMOGLOBIN; HAPLOTYPES; HEMOGLOBIN, SICKLE; HUMANS; HYDROXYUREA; INDIA; MALE; YOUNG ADULT;

EID: 58049206763     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.08.003     Document Type: Article

References (38)

1. Bhatia H.M., and Rao V.R. Genetic Atlas of the Indian Tribes (1987), Institute of Immunohaematology (ICMR), Bombay
2. Mohanty D., and Mukherjee M. Sickle cell disease in India. Curr. Opin. Hematol. 9 (2002) 117-122
3. Kar B.C., Satapathy R.K., Kulozik A.E., Kulozik M., Sirr S., Serjeant B.E., and Serjeant G.R. Sickle cell disease in Orissa State, India. Lancet 2 (1986) 1198-1201
4. Brittenham G., Lozoff B., Harris J.W., Mayson S.M., Miller A., and Huisman T.H.J. Sickle cell anemia and trait in Southern India: further studies. Am. J. Hematol. 6 (1979) 107-123
5. Perrine R.P., Brown M.J., Clegg J.B., Weatherall D.J., and May A. Benign sickle-cell anaemia. Lancet 2 (1972) 1163-1167
6. Mukherjee M.B., Lu C.Y., Ducrocq R., Gangakhedkar R.R., Colah R.B., Kadam M.D., Mohanty D., Nagel R.L., and Krishnamoorthy R. Effect of α-thalassemia on sickle-cell anemia linked to the Arab-Indian haplotype in India. Am. J. Hematol. 55 (1997) 104-109
7. Platt O.S., Orkin S.H., Dover G., Beardsley G.P., Miller B., and Nathan D.G. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. 74 (1984) 652-656
8. Letvin N.L., Linch D.C., Beardsley G.P., McIntyre K.W., and Nathan D.G. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N. Engl. J. Med. 310 (1984) 869-873
9. Platt O.S. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 358 (2008) 1362-1369
10. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., McMahon R.P., and Bonds D.R. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332 (1995) 1317-1322
11. Steinberg M.H., Lu Z.H., Barton F.B., Terrin M.L., Charache S., and Dover G.J. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 89 (1997) 1078-1088
12. Fibach E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. Hemoglobin 22 (1998) 445-458
13. Bakanay S.M., Dainer E., Clair B., Adekile A., Daitch L., Wells L., Holley L., Smith D., and Kutlar A. Mortality in sickle cell patients on hydroxyurea therapy. Blood 105 (2005) 545-547
14. Italia K., Colah R., and Mohanty D. Evaluation of F cells in sickle cell disorders by flow cytometry - comparison with the Kleihauer-Betke's slide method. Int. J. Lab. Haematol. 29 (2007) 409-414
15. Old J.M. DNA based diagnosis of the haemoglobin disorders. In: Steinberg M.H., Forget B.G., Higgs D.R., and Nagel R.L. (Eds). Disorders of Haemoglobin - Genetics, Pathophysiology and Clinical Management (2001), Cambridge University Press, Cambridge 941-948
16. Colah R.B., Gorakshakar A.C., Lu C.Y., Nadkarni A.H., Desai S.N., Pawar A.R., Lulla C.P., Krishnamoorthy R., and Mohanty D. Application of covalent reverse dot blot hybridisation for rapid prenatal diagnosis of the common Indian thalassemia syndromes. Ind. J. Hematol. Blood Transf. 15 (1997) 10-13
17. Tan A.S., Quah T.C., Low P.S., and Chong S.S. A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for α-thalassaemia. Blood 98 (2001) 250-251
18. s mutation. Blood 79 (1992) 787-792
19. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25 (2000) 169-193
20. Miller B.A., Olivieri N., Salameh M., Ahmed M., Antognetti G., Huisman T.H., Nathan D.G., and Orkin S.H. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N. Engl. J. Med. 316 (1987) 244-250
21. Miller B.A., Salameh M., Ahmed M., Olivieri N., Antognetti G., Orkin S.H., Huisman T.H., and Nathan D.G. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood 70 (1987) 716-720
22. Miller B.A., Salameh M., Ahmed M., Wainscoat J., Antognetti G., Orkin S., Weatherall D., and Nathan D.G. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood 67 (1986) 1404-1410
23. y motif at the - 530 region 5′ to the β-globin gene in the Chinese population. Hemoglobin 19 (1995) 311-316
24. Berg P.E., Mittelman M., Elion J., Labie D., and Schechter A.N. Increased protein binding to a -530 mutation of the human b-globin gene associated with decreased b-globin synthesis. Am. J. Hematol. 36 (1991) 42-47
25. Charache S., Dover G.J., Moore R.D., Eckert S., Ballas S.K., Koshy M., Milner P.F., Orringer E.P., Jr Phillips G., and Platt O.S. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79 (1992) 2555-2565
26. Steinberg M.H., Barton F., Castro O., Pegelow C.H., Ballas S.K., Kutlar A., Orringer E., Bellevue R., Olivieri N., Eckman J., Varma M., Ramirez G., Adler B., Smith W., Carlos T., Ataga K., DeCastro L., Bigelow C., Saunthararajah Y., Telfer M., Vichinsky E., Claster S., Shurin S., Bridges K., Waclawiw M., Bonds D., and Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 (2003) 1645-1651
27. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., Vichinsky E., Redding-Lallinger R., Gee B., Platt O.S., and Ware R.E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94 (1999) 1550-1554
28. Braga L.B., Ferreira A.C., Guimaraes M., Nazario C., Pacheco P., Miranda A., Picanco I., Seixas T., Rosado L., and Amaral V. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study. Hemoglobin 29 (2005) 171-180
29. Hankins J.S., Ware R.E., Rogers Z.R., Wynn L.W., Lane P.A., Scott J.P., and Wang W.C. Long-term Hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106 (2005) 2269-2275
30. Loukopoulos D., Voskaridou E., Kalotychou V., Schina M., Loutradi A., and Theodoropoulos I. Reduction of clinical severity of sickle cell/β-thalassemia with hydroxyurea: the experience of a single center in Greece. Blood Cells Mol. Dis. 26 (2000) 453-466
31. Bradai M., Abad M.T., Pissard S., Lamraoui F., Skopinski L., and Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 102 (2003) 1529-1530
32. Yavarian M., Karimi M., Bakker E., Harteveld C.L., and Giordano P.C. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica 89 (2004) 1172-1178
33. Alebouyeh M., Moussavi F., Haddad-Deylami H., and Vossough P. Hydroxyurea in the treatement of major β-thalassemia and importance of genetic screening. Ann. Hematol. 83 (2004) 430-433
34. Panigrahi I., Dixit A., Arora S., Kabra M., Mahapatra M., Choudhry V.P., and Saxena R. Do α deletions influence hydroxyurea response in thalassemia intermedia. Hematology 10 (2005) 61-63
35. Koren A., Levin C., Dgany O., Kransnov T., Elhasid R., Zalman L., Palmor H., and Tamary H. Response to hydroxyurea therapy in β-thalassemia. Am. J. Hematol. 83 (2008) 366-370
36. Ma Q., Wyszynski D.F., Farrell J.J., Kutlar A., Farrer L.A., Baldwin C.T., and Steinberg M.H. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 7 (2007) 386-394
37. Lettre G., Sankaran V.G., Bezerra M.A.C., Araujo A.S., Uda M., Sanna S., Cao A., Schlessinger D., Costa F.F., Hirschhorn J.N., and Orkin S.H. DNA polymorphisms at the BCL11A, HBS1L-MYB and β-globin loci associated with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. (2008) (Epub ahead of print)
38. Little J.A., McGowan V.R., Kato G.J., Partovi K.S., Feld J.J., Maric I., Martyr S., Taylor J.G., Machado R.F., Heller T., Castro O., and Gladwin M.T. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 91 (2006) 1076-1083